新型血蛋白生物标志物:阿尔茨海默病的时间依赖性预测模型
Tianchi Zhuang1, Yingqi Yang2, Haili Ren1
1School of Nursing, Nanjing Medical University, Nanjing, Jiangsu 211166, PR China.
Archives of gerontology and geriatrics
|October 20, 2024
概括
这项研究确定了七种血蛋白签名,可以预测未来的阿尔茨海默病 (AD) 发病. 开发的风险模型显示出强大的预测性能,有助于早期AD查和干预.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物发现发现
- 蛋白质组学是指蛋白质组学.
背景情况:
- 准确预测阿尔茨海默病 (AD) 对疾病管理至关重要.
- 新的血蛋白生物标志物正在研究用于预测AD发病率.
- 了解这些生物标志物与AD的生物学相关性至关重要.
研究的目的:
- 开发一种新的风险预测模型,用于未来的阿尔茨海默病 (AD) 发病率,使用血蛋白生物标志物.
- 分析已识别的血蛋白签名与AD发病率之间的生物相关性.
- 评估开发模型的预测性能和稳定性.
主要方法:
- 利用了来自阿尔茨海默病神经成像计划 (ADNI) 队列的440名参与者 (年龄≥60岁) 的纵向数据.
- 采用考克斯回归,LASSO回归,并对基线血蛋白质组学数据进行交叉验证,以确定预测性蛋白质特征.
- 构建了一个多变量Cox比例危险模型,用时间依赖的ROC和Kaplan-Meier曲线评估性能;分析了与临床数据的相关性,并进行了局部化和门德尔随机化分析.
主要成果:
- 确定了七种血蛋白签名 (APOE,CGA,CRP,CCL26,CCL20,NRCAM,PYY),可以独立预测未来的AD发病率.
- 风险预测模型在4年至8年的预测中达到0.77-0.76的AUC值,并在3年至12年保持稳定 (ROC≥0.74).
- 蛋白质标志与AD风险和发病时间有显著的相关性;NRCAM和PYY显示AD患者的血液下调,而APOE,CGA和NRCAM在AD大脑下调.
结论:
- 成功地确定了血蛋白签名作为未来AD发病的独立预测因素.
- 开发的风险预测模型显示了强大的预测性能和时间稳定性.
- 血蛋白签名为动态AD风险预测提供了有前途的实用性,促进早期查和干预策略.
更多相关视频
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.8K
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
965
相关概念视频
Alzheimer's Disease: Overview
449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
